Therefore, therapeutics designed to inhibit RIP1 and RIP3 kinase activity in hepatocytes would likely be beneficial in reducing liver injury associated with consumption of high fat diets and associated obesity. Here, RIPK1 is linked to obesity due to melanocortin 4 receptor deficiency.